Company Overview and News

0
Heron Resources (HRLDF) Presents At Noosa Mining And Exploration Investor Conference - Slideshow

2018-07-19 seekingalpha
The following slide deck was published by Heron Resources Limited HRR in conjunction with this event.
HRR HRLDF HER

0
Alchemy Resources commences drilling at West Lynn nickel-cobalt project

2018-07-13 proactiveinvestors.com.au
Alchemy Resources Ltd (ASX:ALY) has begun drilling at its West Lynn project in New South Wales with the aim of advancing its nickel-cobalt exploration target to an inferred resource.
HRR ALY HER

0
Woodlawn Project Remains on Track to Deliver 1st Concentrate in Q1 2019

2018-06-26 globenewswire
Sydney, Australia, June 26, 2018 (GLOBE NEWSWIRE) -- Heron Resources Limited (ASX:HRR “Heron” or the “Company”) is pleased to provide the following update on the Company’s wholly owned Woodlawn Zinc-Copper Project in New South Wales, Australia. Significant progress continues to be made at the site, and construction is progressing on track and within budget.
HRR HER

0
Heron Resources on track for 2019 production at Woodlawn

2018-06-26 australianmining.com.au
Heron Resources’ Woodlawn zinc-copper project, which is 250km southwest of Sydney, remains on track for the delivery of its first concentrate in early 2019.
HRR HER

0
Heron awards transport contract for Woodlawn zinc-copper project

2018-06-21 australianmining.com.au
Heron Resources has awarded the road and rail logistics services contract for its Woodlawn zinc-copper project in New South Wales to local supplier Crawfords Freightlines.
HRR HER

0
Heron Awards Concentrate Logistics Contract

2018-06-21 globenewswire
Sydney, Australia, June 21, 2018 (GLOBE NEWSWIRE) -- Heron Resources Limited (ASX:HRR, “Heron” or the “Company”) is pleased to announce the award of a sigificant transportation services contract with Crawfords Freightlines Pty Ltd (“Crawfords”) for its wholly owned Woodlawn Zinc-Copper Project in New South Wales, Australia.
HRR HER

0
Heron Locks in Electricity Supply Contract to Power Woodlawn Mine

2018-06-18 globenewswire
Sydney, Australia, June 18, 2018 (GLOBE NEWSWIRE) -- Heron Resources Limited (ASX:HRR, “Heron” or the “Company”) is pleased to announce it has signed an electricity supply contract with a major electricity retailer to power the Woodlawn Mine through the commissioning phase and into production in early 2019.
HRR HER

4
Heron Resources Files Application to Cease to be a Reporting Issuer in Canada

2018-06-11 globenewswire
SYDNEY, Australia, June 11, 2018 (GLOBE NEWSWIRE) -- Heron Resources Limited (“Heron” or the “Company”) (ASX:HRR) announces that the ordinary shares of Heron were voluntarily delisted from the Toronto Stock Exchange on March 29, 2018. Since that time, the Company has remained a reporting issuer in Ontario, Canada.
HRR MALRY MALRF MIN HER

0
Heron’s Drilling of G2 & Lisa Lenses at Woodlawn Deliver High Grade Assays

2018-06-04 globenewswire
Sydney, Australia, June 04, 2018 (GLOBE NEWSWIRE) -- Heron Resources Limited (ASX:HRR “Heron” or the “Company”) is pleased to report that it has received assays for the recently intersected base-metal mineralisation at its wholly-owned Woodlawn Zinc-Copper Project, located 250km south-west of Sydney, New South Wales, Australia. The intercepts at both the G2 and Lisa Lens positions extend the known limits of the mineralisation in these areas and is expected to provide additional early-stage production for the operation.
HRR HER

0
Heron Completes Draw-Down of First Tranche of US$20M Debt; Project More Than 50% Complete

2018-05-31 globenewswire
Sydney, Australia, May 31, 2018 (GLOBE NEWSWIRE) -- Heron Resources Limited (ASX:HRR, “Heron” or the “Company”) is pleased to announce it has completed the draw-down of the first tranche of US$20M of debt from Orion Mine Finance. As announced to the market on 30 June 2017, the total debt provided by Orion Mine Finance is US$60M; the remaining US$40M remains undrawn and is available to Heron.
HRR HER

4
Heron Awards Key Tailings Mining Contracts

2018-05-22 globenewswire
Heron Resources Limited (ASX:HRR, “Heron” or the “Company”) is pleased to announce the award of two contracts relating to the provision of equipment supply and mining services for the reclamation of tailings for reprocessing at its wholly owned Woodlawn Zinc-Copper Project in New South Wales, Australia, which is currently under construction and due to commence commissioning at the end of 2018.
HRR MALRY MALRF MIN HER

0
Heron awards Woodlawn contracts

2018-05-21 australianmining.com.au
Heron Resources has awarded two key contracts for the Woodlawn zinc-copper project in New South Wales.
HRR HER

0
Heron’s G2 Lens Delivers Strong Metallurgical Results

2018-05-08 globenewswire
Sydney, Australia, May 08, 2018 (GLOBE NEWSWIRE) -- Heron Resources Limited (ASX:HRR, “Heron” or the “Company”) is pleased to report results from a metallurgical testwork program undertaken on the shallow G2 Lens at its wholly owned Woodlawn Zinc-Copper Project in New South Wales, Australia. The G2 Lens represents the first mineralisation to be accessed in the underground operation and is not currently reported within the operations Ore Reserves.
HRR HER

0
Heron Resources (HRLDF) Presents At 121 Mining Investment - Slideshow

2018-04-23 seekingalpha
The following slide deck was published by Heron Resources Limited HRR in conjunction with this event.
HRR HRLDF HER

0
Heron’s Peelwood Project - EM Drill Targets Identified

2018-04-23 globenewswire
Sydney, Australia, April 23, 2018 (GLOBE NEWSWIRE) -- Heron Resources Limited (ASX:HRR, “Heron” or the “Company”) is pleased to report that a number of drill ready EM anomalies have been identified at its wholly owned Peelwood base metal project located 105 km north of the Company’s Woodlawn Zinc-Copper Project in New South Wales, Australia.
HRR HER

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...